In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Janux Therapeutics Inc (NASDAQ: JANX) closed the day trading at $30.91 down -0.06% from the previous closing price of $30.93. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 0.71 million shares were traded. JANX stock price reached its highest trading level at $31.27 during the session, while it also had its lowest trading level at $30.375.
Ratios:
For a better understanding of JANX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 59.21 and its Current Ratio is at 59.21. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 03, 2024, Reiterated its Buy rating but revised its target price to $70 from $63 previously.
On December 03, 2024, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $82 to $100.
On November 22, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $79.Leerink Partners initiated its Outperform rating on November 22, 2024, with a $79 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when RA CAPITAL MANAGEMENT, L.P. bought 372,093 shares for $30.78 per share. The transaction valued at 11,453,023 led to the insider holds 10,031,081 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 341,742 shares of JANX for $10,471,352 on Mar 05 ’25. The Director now owns 9,658,988 shares after completing the transaction at $30.64 per share. On Mar 07 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 110,206 shares for $31.02 each. As a result, the insider paid 3,418,590 and bolstered with 10,141,287 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1826938624 and an Enterprise Value of 824792064. For the stock, the TTM Price-to-Sale (P/S) ratio is 172.52 while its Price-to-Book (P/B) ratio in mrq is 1.79. Its current Enterprise Value per Revenue stands at 77.899 whereas that against EBITDA is -8.522.
Stock Price History:
The Beta on a monthly basis for JANX is 3.19, which has changed by -0.22434127 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $28.92. The 50-Day Moving Average of the stock is -19.32%, while the 200-Day Moving Average is calculated to be -31.79%.
Shares Statistics:
Over the past 3-months, JANX traded about 955.44K shares per day on average, while over the past 10 days, JANX traded about 725420 shares per day. A total of 59.06M shares are outstanding, with a floating share count of 49.57M. Insiders hold about 16.13% of the company’s shares, while institutions hold 107.90% stake in the company. Shares short for JANX as of 1740700800 were 9371657 with a Short Ratio of 9.81, compared to 1738281600 on 8131557. Therefore, it implies a Short% of Shares Outstanding of 9371657 and a Short% of Float of 28.120002.
